Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2004

Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci P M, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci P G, Biffi R, Orsi F, Cinieri S, Goldhirsch A

Abstract excerpt

BACKGROUND: To analyze the influence of the prothrombotic gene mutation factor V G1691A (factor V Leiden) and prothrombin G20210A on the risk of a first episode of catheter-related deep venous thrombosis (DVT) in a group of patients with breast cancer treated with chemotherapy. PATIENTS AND METHO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Cohort Studies

Share to Factor V

Share to Hybridization, Genetic

Share to Prothrombin

Share to Venous Thrombosis

Source

Identifiers

PMID: 15033664
DOI: 10.1093/annonc/mdh146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15033664-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.PMID 15033664Read ↗

Malignancies, prothrombotic mutations, and the risk of venous thrombosis.Semantic proximity Read ↗

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.Semantic proximity Read ↗

Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.Semantic proximity Read ↗

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.Semantic proximity Read ↗

Adjuvant therapy in breast cancer and venous thromboembolism.Semantic proximity Read ↗

PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer.Semantic proximity Read ↗

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.Semantic proximity Read ↗

The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients1.Semantic proximity Read ↗

Thrombophilia gene mutations predict venous thromboembolism in ambulatory cancer patients receiving chemotherapy.Semantic proximity Read ↗

Thrombophilia and risk of venous thrombosis in patients with cancer.Semantic proximity Read ↗

Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.Semantic proximity Read ↗

Factor V Leiden mutation does not account for central venous catheter-related thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.